PTC Therapeutics Exec VP, CLO Mark Elliott Boulding disposes of $12,337 of common shares
PTC Therapeutics Executive VP and CLO Mark Elliott Boulding exercised stock options for 192 shares at $39.42 on Oct. 9, 2026. He sold 192 shares the same day at a weighted average price of $64.26. Directly held common stock totaled 105,272 shares following the transactions. Disclaimer: This news brief was created by Pu